StockCall Scrutinizes STJ, HOLX, NAVB, EW, and RMD
StockCall.com Provides Stock Research on St. Jude Medical Inc., Hologic Inc., Navidea Biopharmaceuticals Inc., Edwards Lifesciences Corp., and ResMed Inc.
Sat May 11, 2013
Hologic Downgraded to "Outperform" at Raymond James
They currently have a $23.00 target price on the stock, down from their previous target price of $27.00. Hologic traded up 3.27% on Tuesday, hitting $21.18. Hologic has a 52-week low of $16.18 and a 52-week high of $23.96. The stock's 50-day moving average is currently $21.99. The company's market cap is $5.680 billion.
Thu May 09, 2013
Hologic's Neutral Rating Reaffirmed at Zacks
's stock had its "neutral" rating reaffirmed by Zacks in a report released on Thursday, AnalystRatingsNetwork.com reports.
Hologic Appoints Scott Garrett to Board
Hologic , a manufacturer of diagnostics products, medical imaging systems and surgical products has appointed Scott T. Garrett to the Company's newly expanded board of directors.
Wed May 08, 2013
Recent Financials May Not Be Entirely Fair To Hologic
I have no qualms with those who believe it is the responsibility of the management of public companies to communicate clearly and accurately with investors about the current state of the business and the likely near-term conditions.
Free Research Reports on ARUN, HOLX, MELI and RKUS Issued by the Paragon Report
As a leading provider of free in depth reports and timely market updates, Paragon is an essential resource for hundreds of thousands of investors across the country.
Tue May 07, 2013
Hologic PT Lowered to $26.00
The firm currently has a "buy" rating on the stock. A number of other firms have also recently commented on HOLX.
Mon May 06, 2013
Hologic Management Discusses Q2 2013 Results - Earnings Call Transcript
Good day, everyone, and welcome to the Hologic Inc. Second Quarter Fiscal 2013 Earnings Conference Call.
Hologic (HOLX) Updates FY13 Earnings Guidance
Hologic updated its FY13 earnings guidance on Monday. The company provided earnings per share guidance of $1.54-1.56 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.58, AnalystRatingsNetwork.com reports.
Hologic (HOLX) Posts Quarterly Earnings, Beats Expectations By $0.01 EPS
Hologic announced its earnings results on Monday. The company reported $0.35 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.34 by $0.01, Stock Ratings Network reports.
Mon Apr 29, 2013
DiagnoCure's Update Presentation during the Annual and Special Meeting of Shareholders
The presentation will be available on DiagnoCure's website at www.diagnocure.com through a link on the Investors page; presentations, available from DiagnoCure is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions.